Chime Biologics
Wuhan, China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Chime Biologics
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Wuhan, China
- Modalities
- Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Biosimilars, ADC (announced/expanding), Drug Product / Fill-Finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Chime Biologics
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Biosimilars, ADC (announced/expanding), Drug Product / Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development - PR Newswire
Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision - BioPharma APAC
Chime looks to expand manufacturing capacity and establish European presence - Pharmaceutical Technology
Daewoong partners with Chime Biologics on Dupixent biosimilar - koreabiomed.com
Daewoong Pharmaceutical announced on the 2nd that it has signed a consignment development, productio.. - 매일경제
Daewoong Pharmaceutical enters Dupixent biosimilar race to tap Korea market - CHOSUNBIZ - Chosunbiz
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion - PR Newswire
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5 - BioSpace
Chime Bio, flush with $190M, blueprints major biomanufacturing boost in China - Fierce Pharma
Chime Biologics, Hope Medicine Partner on Antibody Drug HMI-115 - Contract Pharma
Frequently Asked Questions About Chime Biologics
What is Chime Biologics's CDMO Signal Score?
Chime Biologics has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Chime Biologics for a manufacturing program?
Use the free AI matchmaker to compare Chime Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
Monoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Plasmid DNA, Lentiviral (process development), Fill-Finish (vial, PFS, lyophilized, BFS)
Canton Biologics
Guangzhou, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Plasmid DNA, Lentiviral, CAR-T, AAV
Boehringer Ingelheim BioXcellence
Ingelheim am Main, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish